Physician profile
Marcus W Lee
NPI 1689870982
$68,251.48
in general payments reported to CMS, 2019-2025
41 companies · $15K in 2025
The $15K reported for 2025 was more than what 93% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $960 · 2020: $5,907 · 2021: $9,260 · 2022: $16K · 2023: $12K · 2024: $8,954 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $29K · Food and Beverage: $5,710 · Travel and Lodging: $1,236.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $28,875.00 |
| Food and Beverage | $5,709.52 |
| Travel and Lodging | $1,236.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $58,996.63 | 2020-2025 | Valtoco |
| Ucb, INC. | $1,898.12 | 2019-2025 | Fintepla, Briviact, Nayzilam |
| Jazz Pharmaceuticals INC. | $1,287.17 | 2022-2025 | Epidiolex |
| Eisai INC. | $920.74 | 2019-2023 | |
| Sk Life Science, INC. | $870.79 | 2020-2025 | |
| Sunovion Pharmaceuticals INC. | $816.48 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $441.59 | 2019-2025 | Qelbree |
| Ptc Therapeutics, INC. | $400.76 | 2019-2024 | Emflaza |
| Greenwich Biosciences, INC. | $395.68 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $283.78 | 2023-2025 | Daybue |
| Zogenix INC. | $222.25 | 2020-2021 | |
| Itf Therapeutics LLC | $187.27 | 2024-2025 | |
| Amicus Therapeutics, INC. | $167.03 | 2022-2023 | Galafold |
| Abbvie INC. | $148.69 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $121.16 | 2023 | Aptiom |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $107.22 | 2023-2025 | Azstarys |
| Genentech USA, INC. | $101.61 | 2022-2025 | Evrysdi |
| Biogen, INC. | $99.55 | 2019-2025 | Skyclarys, Skyclarys, Spinraza |
| Sarepta Therapeutics, INC. | $89.39 | 2023-2024 | Elevidys |
| Pyros Pharmaceuticals, INC. | $78.55 | 2024 | Vigpoder |
| Abbott Laboratories | $71.50 | 2023 | Amplatzer Piccolo |
| Piramal Critical Care | $62.26 | 2020-2025 | |
| Tris Pharma INC | $58.66 | 2024-2025 | Dyanavel Xr, Onyda Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $48.92 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $43.87 | 2023 | Oxlumo |
| Ironshore Pharmaceuticals INC. | $40.02 | 2019 | |
| Collegium Pharmaceutical, INC. | $33.37 | 2025 | Jornay Pm |
| Springworks Therapeutics, INC. | $26.15 | 2025 | Gomekli |
| Orchard Therapeutics North America | $21.63 | 2025 | Lenmeldy |
| Catalyst Pharmaceuticals, INC. | $20.93 | 2023 | Fycompa |
| Irhythm Technologies, INC. | $20.10 | 2024 | Zio Monitor, Zio Xt Patch |
| Aucta Pharmaceuticals, INC. | $18.99 | 2024 | Motpoly Xr |
| Medtronic, INC. | $18.97 | 2024 | Synchromedii |
| Azurity Pharmaceuticals, INC. | $18.84 | 2023 | Gliadel |
| Metacel Pharmaceuticals LLC | $18.30 | 2025 | Ozobax |
| Kedrion Biopharma, INC. | $17.78 | 2024 | Koate, Kedrab, Gammaked |
| Upsher-Smith Laboratories LLC | $17.01 | 2025 | |
| Immedica Pharma US, INC. | $16.02 | 2023 | |
| Ns Pharma, INC. | $15.73 | 2021 | |
| Arbor Pharmaceuticals, INC. | $14.26 | 2022 | |
| Biomarin Pharmaceutical INC. | $13.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcus Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.